"Multiple-center randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock." by Jay Steingrub, MD

Article

Multiple-center randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock.

All Scholarly Works

Jay Steingrub, MD, Baystate Health

Document Type

Article, Peer-reviewed

Publication Date

1-1-2004

Citation Information

Lopez A, Lorenta JA, Steingrub J, Bakker J, McLuckie A, Willatts S, Brockway M, Anzueto A, Holzapfel L, Breen D, Silverman MS, Takala J, Donaldson J, Arneson C, Grove G, Grossman S, Grover R. Multiple-center randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004 Jan;32(1):21-30.